Latest Commercialization News

Core Energy Minerals has appointed Anthony Greenaway as Managing Director, aiming to leverage his extensive exploration expertise to advance its uranium and rare earth projects in South Australia and Brazil.

PYC Therapeutics has restructured its Board and executive team to steer the company through pivotal clinical milestones expected by the end of 2027. The changes signal a strategic push toward late-stage development of its RNA-based drug candidates.

HealthCo Healthcare & Wellness REIT has collected all outstanding rent from Healthscope and extended a rent deferral to support the ongoing sale process, while suspending distributions to preserve liquidity.

LTR Pharma has acquired a one-third equity stake in LevOmega Pty Ltd at no cost to shareholders, positioning itself in the growing pharmaceutical-grade omega-3 sector. This strategic move complements LTR’s existing intranasal pharmaceutical portfolio and aligns with its innovation-driven growth strategy.

Brazilian Critical Minerals has reported sustained high-grade rare earth element recovery from its in-situ recovery trials at the Ema Project, with pregnant leach solution grades exceeding 5,700 ppm TREO and strong magnet rare earth oxide content.

EVE Health Group has begun distributing Dyspro™, a novel cannabinoid-based treatment for dysmenorrhoea and endometriosis, through a national telehealth partnership. This launch targets a significant unmet need in women’s health with a growing global market.

Everlast Minerals Ltd has issued a Replacement Prospectus for a $4-6 million ASX IPO to fund its mineral sands projects in Bangladesh, focusing on advancing the Gaibandha project towards commercial production.

ChemX Materials Limited has entered voluntary administration following a turbulent quarter marked by convertible note amendments, a trading suspension, and ongoing funding challenges.

1414 Degrees has addressed a sharp rise in its share price and trading volume, attributing the market interest to recent climate policy recommendations and ongoing commercial efforts.

Echo IQ has completed its presentation to the CPT Editorial Panel for a Category III CPT code for EchoSolv AS, with a decision expected from the American Medical Association in the coming weeks. Meanwhile, the company is advancing US deployments and FDA clearance efforts.

Following its recent sale transaction, MPR Australia Limited announces significant board resignations alongside continued leadership under CEO Nathan Wise, signaling a strategic transition phase.

Elanor Investors Group is set to reclaim over 12 million stapled securities from Challenger’s Fidante subsidiary as part of unwinding their strategic partnership, reshaping ownership stakes and signaling a new chapter for the funds manager.